The authors developed a targeted theranostic agent for cancer applications, by conjugating the complex [Ru(bipy)2(bipyCOOH)]2+ (bipyCOOH = 2,2′-bipyridine-4-carboxylic acid) to the EGFR-inhibitor AcetAQZ (N-(4-((4-bromophenyl)amino)quinazolin-7-yl)-2-chloroacetamide), through a triethyleneglycol-derived diamino linker, affording the mono-conjugate 26 and the bis-conjugate 27 (Figure 9). This evidence concerns the gene EGFR and cancer.